3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
53
Lymphoma, Mantle-Cell
34
Lymphoma, Large B-Cell, Diffuse
18
Lymphoma, Follicular
18
Lymphoma
15
Lymphoma, Non-Hodgkin
13
Waldenstrom Macroglobulinemia
12
Lymphoma, B-Cell
12
Recurrence
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia
6
Bronchiolitis Obliterans Syndrome
6
Multiple Myeloma
5
Leukemia, Lymphoid
5
Leukemia, B-Cell
5
Hodgkin Disease
5
Hematologic Neoplasms
4
Burkitt Lymphoma
4
Neoplasms
3
Graft vs Host Disease
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Chromosome 17 deletion
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Cyclophosphamide
12
Whole-Body Irradiation
10
fludarabine phosphate
9
Rituximab
9
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
9
Mycophenolic Acid
7
Filgrastim
7
Etoposide
6
Dexamethasone
6
Busulfan
6
Methotrexate
5
Tacrolimus
4
Carboplatin
4
Bortezomib
4
Vorinostat
3
Thiotepa
3
Radiotherapy
3
Lenalidomide
3
Irinotecan
3
Cytarabine
3
Calcium Dobesilate
3
merphos
2
liposomal amphotericin B
2
laromustine
2
ixabepilone
2
entinostat
2
Transplantation
2
Therapeutics
2
Prednisone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Intraocular Lymphoma
×
ibrutinib
×
Clear all
NCT02542514
2022-04-14
iLOC
The Lymphoma Academic Research Organisation
Phase 2
Completed
52 enrolled